| 초록 |
Target specific delivery of therapeutics using surface-modified nanoparticles has been spotlighted, as this approach can avoid non-specific toxicity and enhance therapeutic efficacy. The aim of this research is to fabricate rabies virus glycoprotein (RVG) peptide-conjugated PLGA nanoparticles and to test their potential in neural cell-targeting gene delivery. PLGA nanoparticles were prepared by a single emulsion method, and then RVG peptide was chemically conjugated to the surface of the nanoparticles. Binding affinity of the nanoparticles to N2A cells was significantly increased by introduction of RVG peptides to PLGA nanoparticles, and was dependent on the peptide density on the surface. A sustained release of siRNA from PLGA nanoparticles was observed for 7 days in vitro. Expression of cyclophilin B (CypB) in N2A cells was significantly reduced when the cells were treated with CypB-siRNA-loaded, RVG-conjugated PLGA nanoparticles, indicating significant gene silencing by RNAi. |
